GlassScriptPhysician profile
David A Wagar
NPI 1356306187
$3,138.76
in general payments reported to CMS, 2019-2025
35 companies · $455 in 2025
The $455 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $89.11 · 2021: $681 · 2022: $488 · 2023: $468 · 2024: $677 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.34 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Aspira Women'S Health INC | $348.88 | 2021-2025 | Ova1 |
| Astellas Pharma US INC | $242.77 | 2021-2025 | Veozah |
| Pfizer INC. | $229.81 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $215.04 | 2022-2025 | |
| Exeltis, USA INC. | $201.05 | 2019-2025 | Slynd |
| Hologic Sales and Service, LLC | $171.01 | 2021-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Renovia INC | $105.07 | 2021 | |
| Myovant Sciences INC. | $97.48 | 2021-2022 | |
| Shield Therapeutics INC | $95.85 | 2024-2025 | |
| Amgen INC. | $95.35 | 2019-2024 | Evenity, Prolia |
| Millicent US INC | $92.03 | 2019-2024 | Femring, Intrarosa |
| Therapeuticsmd, INC. | $85.67 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $81.46 | 2021-2024 | Gardasil 9, Gardasil |
| Daiichi Sankyo INC. | $80.88 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $77.81 | 2023-2024 | Mara Console, Paragard T 380a, Endosee |
| Allergan, INC. | $65.60 | 2019-2020 | |
| Axonics, INC. | $64.46 | 2024 | Axonics |
| Amag Pharmaceuticals, INC. | $61.50 | 2019 | |
| Sumitomo Pharma America, INC. | $45.09 | 2024-2025 | Myfembree, Gemtesa |
| Lupin INC. | $40.12 | 2019 | |
| Organon LLC | $34.82 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $34.22 | 2019-2020 | |
| Sage Therapeutics, LLC | $33.77 | 2021-2024 | |
| Dexcom, INC. | $29.43 | 2025 | Dexcom G6 Transmitter |
| Agile Therapeutics, INC. | $23.71 | 2024 | Twirla |
| Distalmotion US | $19.40 | 2025 | Dexter L6 Robot |
| Mylan Pharmaceuticals INC. | $17.72 | 2022 | |
| Provepharm INC. | $16.50 | 2025 | Bludigo |
| Scynexis, INC. | $16.46 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.31 | 2022 | |
| Becton, Dickinson and Company | $16.13 | 2019 | |
| Meditrina | $14.86 | 2024 | |
| Evofem Biosciences, INC. | $13.16 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.